- Home
- MTA vs KALV Comparison
MTA vs KALV Comparison
Compare MTA & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- KALV
- Stock Information
- Founded
- MTA 1983
- KALV N/A
- Country
- MTA Canada
- KALV United States
- Employees
- MTA N/A
- KALV N/A
- Industry
- MTA
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- MTA
- KALV Health Care
- Exchange
- MTA Nasdaq
- KALV Nasdaq
- Market Cap
- MTA 641.3M
- KALV 551.2M
- IPO Year
- MTA N/A
- KALV N/A
- Fundamental
- Price
- MTA $6.36
- KALV $10.99
- Analyst Decision
- MTA Hold
- KALV Strong Buy
- Analyst Count
- MTA 1
- KALV 8
- Target Price
- MTA $7.50
- KALV $26.43
- AVG Volume (30 Days)
- MTA 882.4K
- KALV 1.0M
- Earning Date
- MTA 11-14-2025
- KALV 11-11-2025
- Dividend Yield
- MTA N/A
- KALV N/A
- EPS Growth
- MTA N/A
- KALV N/A
- EPS
- MTA N/A
- KALV N/A
- Revenue
- MTA $8,167,999.00
- KALV $1,426,000.00
- Revenue This Year
- MTA $117.14
- KALV N/A
- Revenue Next Year
- MTA $69.62
- KALV $234.65
- P/E Ratio
- MTA N/A
- KALV N/A
- Revenue Growth
- MTA 70.70
- KALV N/A
- 52 Week Low
- MTA $2.45
- KALV $7.30
- 52 Week High
- MTA $7.73
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- MTA 44.53
- KALV 41.81
- Support Level
- MTA $6.24
- KALV $10.86
- Resistance Level
- MTA $6.97
- KALV $11.30
- Average True Range (ATR)
- MTA 0.34
- KALV 0.48
- MACD
- MTA -0.14
- KALV 0.04
- Stochastic Oscillator
- MTA 11.26
- KALV 42.11
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.